Our Services
Medical Information
Helpful Resources
Published on: 9/28/2026
GHRP-6 is a synthetic growth hormone releasing peptide that mimics ghrelin to prompt the pituitary gland to release growth hormone, while also sharply increasing appetite. It has never been approved by the FDA or other major regulators for any medical condition, so it is sold only as an unregulated "research" chemical with no guarantee of purity, dose, or sterility, and it is banned in competitive sport. Reported effects range from hunger, water retention, and tingling in the hands to raised blood sugar, insulin resistance, and shifts in cortisol and prolactin, and there are several important safety and legal factors to consider before assuming it is harmless. See below for the full breakdown of how it works, what the evidence does and does not show, and the specific risks that matter most.
If you are dealing with fatigue, low muscle mass, unexplained appetite changes, or other symptoms that made you curious about peptides like GHRP-6, the smarter first step is understanding the cause rather than chasing an unapproved compound. Take a free, instant, online symptom check to see which conditions may explain what you are feeling and which type of clinician to talk to next.
Last reviewed for medical accuracy: 09/28/2026
Growth Hormone Releasing Peptide-6 (GHRP-6) is a synthetic peptide that was developed to stimulate the body’s natural release of growth hormone (GH). It has gained attention in bodybuilding and anti-aging circles for its potential to boost GH levels, support muscle growth and fat loss, and speed up recovery. However, despite these claims, GHRP-6 remains unapproved as a medicine by major regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Below, we explain how GHRP-6 works, outline the evidence (and lack thereof), describe safety concerns, and clarify why it is not an approved therapeutic option.
GHRP-6 belongs to the class of growth hormone secretagogues. It mimics the action of ghrelin, a natural “hunger hormone,” to trigger GH release:
Most of the interest in GHRP-6 comes from small animal studies, limited human trials, and anecdotal reports. Here’s a summary of the areas people often discuss:
Despite theoretical benefits, GHRP-6 has not passed the rigorous standards required for medical approval. Key reasons include:
Insufficient clinical evidence
Safety and long-term risks
Regulatory concerns
Off-label and black-market distribution
Potential for abuse
Because GHRP-6 mimics ghrelin and boosts GH, it can trigger a range of unwanted effects:
If you’re curious about boosting growth hormone levels for medical reasons, there are approved, clinically studied options:
GHRP-6 is not a substitute for professional medical care. If you experience any concerning symptoms—whether related to hormone imbalance, unexpected weight changes, persistent fatigue, or anything that could be life threatening—speak to a healthcare professional promptly. You might also consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker.
GHRP-6 is a synthetic peptide that can boost growth hormone release by activating ghrelin receptors. While it shows promise in laboratory settings, it has not been proven safe or effective for any medical condition in large-scale human trials. Regulatory agencies have not approved GHRP-6 due to insufficient evidence, safety concerns and quality control issues. If you’re considering hormone-related treatments, rely on approved therapies under a doctor’s guidance, maintain a healthy lifestyle, and discuss any serious or painful symptoms with a medical professional. For non-urgent concerns or to explore possible causes of mild symptoms, you can try a free, online symptom check, using the doctor approved Ubie Symptom Checker. Always speak to a doctor about anything that could be life threatening or serious.
(References)
* Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.
* Depoortere I, Thijs T, Peeters T. The contractile effect of the ghrelin receptor antagonist, D-Lys3-GHRP-6, in rat fundic strips is mediated through 5-HT receptors. Eur J Pharmacol. 2006 May 10;537(1-3):160-5. doi: 10.1016/j.ejphar.2006.03.043. Epub 2006 Mar 24. PMID: 16631731.
* Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018 Jan;6(1):45-53. doi: 10.1016/j.sxmr.2017.02.004. Epub 2017 Apr 8. PMID: 28400207; PMCID: PMC5632578.
* Martínez R, Hernández L, Gil L, Carpio Y, Morales A, Herrera F, Rodríguez-Mallón A, Leal Y, Blanco A, Estrada MP. Growth hormone releasing peptide-6 enhanced antibody titers against subunit antigens in mice (BALB/c), tilapia (Oreochromis niloticus) and African catfish (Clarias gariepinus). Vaccine. 2017 Oct 9;35(42):5722-5728. doi: 10.1016/j.vaccine.2017.07.060. PMID: 28893476.
* Ramirez VT, van Oeffelen WEPA, Torres-Fuentes C, Chruścicka B, Druelle C, Golubeva AV, van de Wouw M, Dinan TG, Cryan JF, Schellekens H. Differential functional selectivity and downstream signaling bias of ghrelin receptor antagonists and inverse agonists. FASEB J. 2019 Jan;33(1):518-531. doi: 10.1096/fj.201800655R. Epub 2018 Jul 18. PMID: 30020830.
* Wu B, Cheng S, Liu F, Wei J, Liu Y, Qian T, Ding J, Xu B, Wei J. Novel chimeric peptides based on endomorphins and ghrelin receptor antagonist produced supraspinal antinociceptive effects with reduced acute tolerance in mice. Biochimie. 2025 Jan;228:58-70. doi: 10.1016/j.biochi.2024.08.010. Epub 2024 Aug 13. PMID: 39147011.
* Castro J, Shaikh I, Silo S, Hum C, Carrier M, DiFruscia R, Thouin F, Chan J, Aldana L, Garcia A, Berlanga J, Berryman L. Subchronic safety assessment of CIGB-500 in beagle dog after repeated daily dose administration over 28 days. Regul Toxicol Pharmacol. 2025 May;158:105798. doi: 10.1016/j.yrtph.2025.105798. Epub 2025 Feb 28. PMID: 40024561.
* Zhang X, Cai Y, Chen M, Chen L, Mao Y, He R, Yang P, Xu M, Yan H, Zhao Q. Danshen-Chuanxiong-Honghua ameliorates neurological function and inflammation in traumatic brain injury in rats via modulating Ghrelin/GHSR. J Ethnopharmacol. 2025 Apr 9;345:119625. doi: 10.1016/j.jep.2025.119625. Epub 2025 Mar 10. PMID: 40074098.
* Rodríguez-Ulloa A, Subirós-Martínez N, González LJ, Risco-Acevedo D, Guillén-Nieto GE, Besada V, García-Del-Barco-Herrera D. A discovery-based proteomic approach of epidermal growth factor and growth hormone-releasing peptide-6 in a model of acute ischemic stroke. Pharmacol Rep. 2026 Aug;78(4):1087-1101. doi: 10.1007/s43440-026-00872-4. Epub 2026 Jun 8. PMID: 42258095.
* Hernández-Bernal F, Subirós-Martínez N, Gutiérrez-Ronquillo JH, Colina-Ávila E, Guevara-Rodríguez M, Estenoz-García D, Catasús-Álvarez K, Martín-Bauta Y, Pérez-Saad H, Manso-López AM, Batista-Izquierdo A, González-Dalmau E, Amador-Nuñez T, Muzio-González VL, Guillén-Nieto GE, Garcia-Del-Barco-Herrera D, COURAGE COmbined therapeUtic appRoAch durinG acute strokE Research Group. Phase III Open-Label, Randomized Clinical Trial of Epidermal Growth Factor and Growth Hormone Releasing Hexapeptide in Acute Ischemic Stroke. J Clin Neurosci. 2026 Oct;152:112195. doi: 10.1016/j.jocn.2026.112195. Epub 2026 Jul 16. PMID: 42462342.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.